Admin Posted March 4, 2020 Share Posted March 4, 2020 Jim Marshall (not a doctor) said ... In short It is not a good idea to lower the intensity of bone treatments too early in metastatic, castrate-resistant prostate cancer. Professor Fred Saad recommends only lowering the dose or frequency when: Two years have passed; and The cancer is in check: and Bone markers in blood tests are in check. Monthly standard doses of Xgeva (Denosumab) for two years before tapering is his recommendation, provided cancer and bones check out. Your doctor may choose differently for you for other reasons (kidney health, perhaps). More details All treatments have side effects. Doctors must find a path between having enough dose to keep the disease in check and problems with side effects. Thats why they do clinical trials and other research. Where there are no results of research to guide them, doctors have to look at similar situations. Bone health medicines can have a particularly unpleasant side effect on the jaw, especially if dental health is not good, so doctors looked elsewhere to see if it might be a good idea to reduce the dose. They saw that the bone health in women with osteoporosis (weakened bones) could be helped with a much lower dose than used to be used. So, based on this, they advised their prostate cancer patients that a lower, less frequent dose of bone medicine might work. This was sometimes implemented by prescribing the female version of Denosumab, Prolia. Fred Saad speaks about the issues in this video: https://www.urotoday.com/video-lectures/apccc-2019-conference/video/mediaitem/1475-players-brightcove-net2019-09-16-13-54-57.html?utm_source=newsletter_7537&utm_medium=email&utm_campaign=bone-health-in-advanced-prostate-cancer The article is not on this site. If you click on the link, you will be taken to a site where we do not control the content. So, please be careful about what you read there, and ask your doctor about anything you read. You may need to subscribe to the site to view the article. If the site is temporarily or permanently unavailable, you may receive an error message. Another relevant video [WK: broken link?]: https://www.urotoday.com/component/hwdmediashare/mediaitem/1519-bone-health-agents-in-patients-with-castrate-resistant-prostate-cancer-bertrand-tombal-interview.html?Itemid=1632&utm_source=newsletter_7537&utm_medium=email&utm_campaign=bone-health-in-advanced-prostate-cancer The article is not on this site. If you click on the link, you will be taken to a site where we do not control the content. So, please be careful about what you read there, and ask your doctor about anything you read. You may need to subscribe to the site to view the article. If the site is temporarily or permanently unavailable, you may receive an error message. ... end Jim Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.